Detalhe da pesquisa
1.
Microplastics and Nanoplastics in Atheromas and Cardiovascular Events.
N Engl J Med
; 390(10): 900-910, 2024 Mar 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-38446676
2.
GLP-1 receptor agonists-SGLT-2 inhibitors combination therapy and cardiovascular events after acute myocardial infarction: an observational study in patients with type 2 diabetes.
Cardiovasc Diabetol
; 23(1): 10, 2024 01 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-38184582
3.
Determinants of health status in older patients with transthyretin cardiac amyloidosis: a prospective cohort study.
Aging Clin Exp Res
; 36(1): 89, 2024 Apr 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-38598143
4.
SGLT-2 inhibitors and in-stent restenosis-related events after acute myocardial infarction: an observational study in patients with type 2 diabetes.
BMC Med
; 21(1): 71, 2023 02 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-36829203
5.
Exosomal miR-145 and miR-885 Regulate Thrombosis in COVID-19.
J Pharmacol Exp Ther
; 384(1): 109-115, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35772782
6.
SGLT2-inhibitors effects on the coronary fibrous cap thickness and MACEs in diabetic patients with inducible myocardial ischemia and multi vessels non-obstructive coronary artery stenosis.
Cardiovasc Diabetol
; 22(1): 80, 2023 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37005586
7.
Outcomes in diabetic patients treated with SGLT2-Inhibitors with acute myocardial infarction undergoing PCI: The SGLT2-I AMI PROTECT Registry.
Pharmacol Res
; 187: 106597, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36470546
8.
MiR-15b-5p and PCSK9 inhibition reduces lipopolysaccharide-induced endothelial dysfunction by targeting SIRT4.
Cell Mol Biol Lett
; 28(1): 66, 2023 Aug 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-37587410
9.
Endothelial Dysfunction Drives CRTd Outcome at 1-Year Follow-Up: A Novel Role as Biomarker for miR-130a-5p.
Int J Mol Sci
; 24(2)2023 Jan 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36675028
10.
Peripheral Neuropathy in Diabetes Mellitus: Pathogenetic Mechanisms and Diagnostic Options.
Int J Mol Sci
; 24(4)2023 Feb 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36834971
11.
Glycated ACE2 reduces anti-remodeling effects of renin-angiotensin system inhibition in human diabetic hearts.
Cardiovasc Diabetol
; 21(1): 146, 2022 08 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35932065
12.
The number of risk factors not at target is associated with cardiovascular risk in a type 2 diabetic population with albuminuria in primary cardiovascular prevention. Post-hoc analysis of the NID-2 trial.
Cardiovasc Diabetol
; 21(1): 235, 2022 11 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-36344978
13.
Infarct size, inflammatory burden, and admission hyperglycemia in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: a multicenter international registry.
Cardiovasc Diabetol
; 21(1): 77, 2022 05 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-35570280
14.
Sodium-glucose cotransporter-2 (SGLT2) expression in diabetic and non-diabetic failing human cardiomyocytes.
Pharmacol Res
; 184: 106448, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36096423
15.
Angiotensin receptor/Neprilysin inhibitor effects in CRTd non-responders: From epigenetic to clinical beside.
Pharmacol Res
; 182: 106303, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35697289
16.
CT angiography-based radiomics as a tool for carotid plaque characterization: a pilot study.
Radiol Med
; 127(7): 743-753, 2022 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-35680773
17.
Current Knowledge on the Pathophysiology of Lean/Normal-Weight Type 2 Diabetes.
Int J Mol Sci
; 24(1)2022 Dec 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-36614099
18.
An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors.
Int J Mol Sci
; 23(7)2022 Mar 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-35409011
19.
Efficacy and durability of multifactorial intervention on mortality and MACEs: a randomized clinical trial in type-2 diabetic kidney disease.
Cardiovasc Diabetol
; 20(1): 145, 2021 07 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-34271948
20.
Glycated ACE2 receptor in diabetes: open door for SARS-COV-2 entry in cardiomyocyte.
Cardiovasc Diabetol
; 20(1): 99, 2021 05 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33962629